Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies.

Subjects

Subjects :

Antibodies, Monoclonal therapeutic use
Antibodies, Neutralizing
Antibodies, Viral
Humans
SARS-CoV-2
Serum
Spike Glycoprotein, Coronavirus
Antineoplastic Agents, Immunological
COVID-19

Details

Language :

English

ISSN :

1469-0691

Volume :

28

Issue :

7

Database :

MEDLINE

Journal :

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Publication Type :

Editorial & Opinion

Accession number :

35304279

Full Text :

https://doi.org/10.1016/j.cmi.2022.03.005